Moderna’s 177% Surge Added $30B—Why Most Investors Should Not Buy It Today
Moderna added roughly $30 billion in one session because a cancer trial worked. If your response is to buy after a 177% jump, you’re not investing—you’re volunteering to be exit liquidity.
Moderna rose 177% in one day on August 19 and added roughly $30 billion in market value. If your first instinct is to smash the buy button this morning, stop: the market has already charged you a very expensive admission fee.
That does not mean the underlying news is rubbish. Quite the opposite. Moderna and Merck delivered something genuinely significant: a late-stage melanoma study of their personalised mRNA therapy, intismeran autogene, combined with Merck’s Keytruda, met its main goal of reducing recurrence versus Keytruda alone and also met a key secondary goal related to the cancer spreading.
That is a big deal for patients, for mRNA science and for Moderna’s future. It is not automatically a big deal for your portfolio at today’s price.
The core story: Moderna finally proved it is more than a COVID trade
For years, Moderna has carried a brutal market problem. Investors knew the company could build and deliver an mRNA vaccine at extraordinary speed; COVID made that point beyond argument. But they also knew the pandemic revenue bonanza was not a forever business.
The hard question was whether Moderna’s platform could become a durable, multi-product machine—or whether it was a one-off winner with a shrinking pile of COVID cash.
Wednesday’s result is the strongest answer Moderna has produced yet.
The treatment is not a traditional preventative vaccine. It is made for an individual patient after genetic analysis of that patient’s tumour. The aim is to train the immune system to recognise mutations specific to the cancer, while Keytruda helps unleash the immune response. In the Phase 3 INTerpath-001 study, the combination was tested after surgery in patients with high-risk melanoma.
The result matters because this was a large, late-stage trial, not a hopeful mouse study or an early safety experiment. Bloomberg reported that it is the first positive final-stage trial for an mRNA-based cancer therapy. That is the sort of milestone that can change how investors value an entire platform.
And the market behaved accordingly. Moderna shares surged 177% on August 19. Merck, the far larger and more diversified partner, also rose sharply, though by much less. That difference tells you exactly what Wall Street thinks happened: Merck gained another promising weapon alongside Keytruda; Moderna may have found the commercial proof point its whole post-COVID story needed.
Why the market repriced Moderna so violently
Markets do not pay up merely because a drug works. They pay up when a result changes the probability distribution of a business.
Before this result, owning Moderna meant accepting several uncomfortable possibilities: COVID revenue could keep fading, its pipeline could take longer than hoped to produce meaningful sales, and mRNA’s usefulness beyond infectious disease could remain an expensive theory.
Now the theory has a serious piece of evidence behind it.
Earlier Phase 2b follow-up data had already been encouraging. Moderna and Merck said that, after five years, the combination reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared with Keytruda alone in that earlier study. The new Phase 3 result is important because it takes the programme from “interesting data” to “this could realistically become a product.”
That shift has implications well beyond melanoma. Merck and Moderna have been studying the approach across other cancers, including lung, kidney and bladder cancers. If an individualised mRNA therapy can be manufactured reliably, approved by regulators and adopted by oncologists, the addressable market becomes much larger than one skin-cancer setting.
That is why the share-price move was so savage. Investors were not repricing next quarter’s revenue. They were attempting to value a possible new cancer-treatment platform in a single trading session.
There is a lesson there for founders too: markets will forgive years of doubt when you finally produce evidence that destroys the central bear case. But they will not give you credit for a beautiful slide deck. Moderna’s valuation changed because a hard clinical endpoint was met.
The bit everyone chasing the ticker is ignoring
A good clinical result and a good stock purchase are two completely different things.
This is where retail investors repeatedly punch themselves in the face. They see a real breakthrough, correctly conclude it is meaningful, then make the leap that the shares must still be cheap after a near-tripling in a day. That leap is where the money gets lost.
The Phase 3 topline result is not the same thing as regulatory approval. It is not a launch. It is not revenue. It is not proof that every one of Moderna’s other oncology programmes will work. And it is definitely not proof that every patient will have access to the therapy at a price health systems can bear.
Personalised treatments are operationally hard. Each patient’s tumour must be analysed, a bespoke therapy designed and manufactured, then delivered on a timeline that works clinically. That is an extraordinary bit of science, but science does not exempt a business from execution risk.
There is also a valuation issue. A share price that climbs 177% in one session has already absorbed a mountain of optimism. Some of that may prove justified. Some of it will be traders, short covering and people chasing a chart because they hate the idea of missing the next big thing.
Reuters reported that short sellers faced about $4.8 billion in mark-to-market losses during the rally. That is not a trivial footnote. When heavily shorted stocks explode, forced buying can make a move much more violent than a sober assessment of long-term value. It can also make the comedown nasty once the forced buying ends.
I have made enough money—and lost enough—to know that buying a great story at any price is one of the most expensive ways to feel clever for 24 hours.
The contrarian view: Merck may be the cleaner wealth-building play
The sexy trade is Moderna. It is the company whose chart looks like it has been fired from a cannon.
The more boring thought is Merck.
Merck brings Keytruda, oncology infrastructure, regulatory experience, commercial muscle and a diversified business. Moderna brings the platform upside and therefore carries the bigger upside if this becomes a broad cancer franchise. But it also carries a lot more dependency on the outcome.
That does not mean Merck is automatically cheap. Nothing is automatically cheap just because it is less exciting. But for an investor who wants exposure to this result without betting the farm on one company’s pipeline, Merck deserves more attention than it will get from the crowd.
The overlooked angle is even simpler: you do not have to own either stock today.
There is a childish belief in markets that every major development requires an immediate trade. Rubbish. You can watch the regulatory path, wait for fuller data, track manufacturing plans, see how reimbursement discussions develop and decide later whether the economics justify the valuation.
The market will open again tomorrow. It always does.
What this means for you
First, separate the company from the stock. Moderna’s news is excellent for the company. That does not answer whether Moderna shares are attractive after a 177% single-day jump.
Second, never let one headline determine a position size. If you absolutely want exposure, make it a deliberately small, pre-defined speculative allocation—not money earmarked for retirement, a house deposit or your operating cash buffer. A breakthrough can still produce a horrible entry price.
Third, make a checklist before you buy biotech: What is the regulatory path? What does manufacturing look like? Who pays? How large is the realistic patient population? What competitors exist? What future revenue is already reflected in the market cap? If you cannot answer those questions, you are buying excitement, not an asset.
Fourth, take the broader lesson seriously. The biggest fortunes are usually made by owning exceptional businesses before the proof becomes obvious, then holding through the boring, uncomfortable years. They are rarely made by chasing a stock after everyone on the internet has discovered it at once.
Moderna and Merck may have opened an important new chapter for mRNA cancer treatment. That is worth watching closely. Just do not confuse a scientific milestone with permission to abandon discipline.
The market rewards patience far more reliably than adrenaline.